|Awarded On||November 02, 2011|
|Title||Identify signature profile for sensitivity/resistance to PI3K pathway inhibitors to predict response to therapy in Glioblastoma.|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||W. K. Alfred Yung|
|Cancer Sites||Brain and Other Nervous System|
Cancer treatment is entering an era in which information from the human genome project is being translated most readily into personalized treatment. The Cancer Genome Atlas Network (TCGA) recently described a robust gene expression-based molecular classification of glioblastoma multiforme (GBMs) into 4 distinct subgroups, and the next step is to determine if the molecular characteristics can be translated to therapeutic responsiveness. To achieve this, we need to develop efficient approaches to identify the role and function of candidate genes/pathways that are altered and characterize these molecular subgroups. The goal of this project is to develop a systematic platform for identifying the...